Explore
Validate
Learn
Western blotAntibody data
- Antibody Data
- Antigen structure
- References [2]
- Comments [0]
- Validations
- Western blot [5]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA1-41114 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- EZH1 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Description
- This antibody is 86% homologous to rat and canine. Suggested positive control: antigen standard for EZH1 (transient overexpression lysate), human or mouse spleen.
- Reactivity
- Human, Mouse
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µg
- Concentration
- 1 mg/mL
- Storage
- Store at 4°C short term. For long term storage, store at -20°C, avoiding freeze/thaw cycles.
Submitted references EED-Targeted PROTACs Degrade EED, EZH2, and SUZ12 in the PRC2 Complex.
DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.
Hsu JH, Rasmusson T, Robinson J, Pachl F, Read J, Kawatkar S, O' Donovan DH, Bagal S, Code E, Rawlins P, Argyrou A, Tomlinson R, Gao N, Zhu X, Chiarparin E, Jacques K, Shen M, Woods H, Bednarski E, Wilson DM, Drew L, Castaldi MP, Fawell S, Bloecher A
Cell chemical biology 2020 Jan 16;27(1):41-46.e17
Cell chemical biology 2020 Jan 16;27(1):41-46.e17
DNA methylation in small cell lung cancer defines distinct disease subtypes and correlates with high expression of EZH2.
Poirier JT, Gardner EE, Connis N, Moreira AL, de Stanchina E, Hann CL, Rudin CM
Oncogene 2015 Nov 26;34(48):5869-78
Oncogene 2015 Nov 26;34(48):5869-78
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot detection of EZH1 in mouse (lane 1) and human (lane 2) spleen lysate using a EZH1 polyclonal antibody (Product # PA1-41114) at 2 µg/mL.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot was performed using Anti-EZH1 Polyclonal Antibody (Product # PA1-41114) and a ~90 kDa band corresponding to Histone-lysine N-methyltransferase EZH1 was observed along with few uncharacterised band (*) in the range of 80 kDa to 20 kDa across cell lines tested. Nuclear enriched extracts (30 µg lysate) of MOLT-4 (Lane 1), HCT 116 (Lane 2), TNFa treated HCT 116 (Lane 3), THP-1 (Lane 4), HEL 92.1.7 (Lane 5) and K-562 (Lane 6) were electrophoresed using NuPAGE™ 4-12% Bis-Tris Protein Gel (Product # NP0321BOX). Resolved proteins were then transferred onto a nitrocellulose membrane (Product # IB23001) by iBlot® 2 Dry Blotting System (Product # IB21001). The blot was probed with the primary antibody (1:1000 dilution) and detected by chemiluminescence with Goat anti-Rabbit IgG (H+L) Superclonal™ Recombinant Secondary Antibody, HRP (Product # A27036,1:20000 dilution using the iBright™ FL1500 Imaging System (Product # A44115). Chemiluminescent detection was performed using SuperSignal™ West Dura Extended Duration Substrate (Product # 34076).
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of EZH1 in (A ) Ramos cells lysate, (B) Daudi cells lysate, (C) Peptide blocked. Samples were incubated in EZH1 polyclonal antibody (Product # PA1-41114) using a dilution of 2 µg/mL.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Knockdown of Histone-lysine N-methyltransferase EZH1 was achieved by transfecting HCT 116 with Histone-lysine N-methyltransferase EZH1 specific siRNAs (Silencer® select Product # s4913, s4914). Western blot analysis (Fig. a) was performed using Nuclear enriched extracts from the Histone-lysine N-methyltransferase EZH1 knockdown cells (lane 3), non-targeting scrambled siRNA transfected cells (lane 2) and untransfected cells (lane 1). The blot was probed with EZH1 Polyclonal Antibody (Product # PA1-41114, 1:1000 dilution ) and Goat anti-Rabbit IgG (H+L) Superclonal™ Recombinant Secondary Antibody, HRP (Product # A27036, 1:20000 dilution). Densitometric analysis of this western blot is shown in histogram (Fig. b). Decrease in signal upon siRNA mediated knock down confirms that antibody is specific to Histone-lysine N-methyltransferase EZH1.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of EZH1 in mouse and human spleen lysate. Samples were incubated in EZH1 polyclonal antibody (Product # PA1-41114 using a dilution of 2 µg/mL. Lane 1: mouse spleen lysate; Lane 2: human spleen lysate.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 7 Pharmacologic inhibition of EZH2 in SCLC inhibits growth in vitro and in vivo A) EZH1 and EZH2 are consistently expressed in a panel of SCLC PDXs as measured by Western blot B) Ex vivo growth of the SCLC PDX LX92 is significantly inhibited by the EZH2 inhibitors EPZ-5687, GSK343, and UNC1999 as measured by resazurin conversion (2-way ANOVA, adjusted for multiple comparisons by the method of Dunnet) C) Western blot analysis of day 7 lysates from LX92 lysates treated with various EZH2 inhibitors. D) In vivo growth of the SCLC PDX LX92 is significantly inhibited by the EZH2 inhibitor EPZ-6438. E) Western blot analysis of endpoint LX92 tumor lysates treated with various EPZ-6438 treatment schedules. Tumors with growth inhibition greater than the median (TGI>median) for each treatment group were pooled separately from those with less robust response (TGI
